Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Post-Transplant Events

Pegfilgrastim after high-dose chemotherapy and autologous peripheral blood stem cell transplant: phase II study

Bone Marrow Transplantation volume 35, pages 1165–1169 (2005)Cite this article

Summary:

Pegfilgrastim is equivalent to daily filgrastim after standard dose chemotherapy in decreasing the duration of neutropenia. Daily filgrastim started within 1–4 days after autologous stem cell transplant (ASCT) leads to significant decrease in time to neutrophil engraftment. We undertook a study of pegfilgrastim after high-dose chemotherapy (HDC) and ASCT. In all, 38 patients with multiple myeloma or lymphoma, eligible to undergo HDC and ASCT, were enrolled. Patients received a single dose of 6 mg pegfilgrastim subcutaneously 24 h after ASCT. There were no adverse events secondary to pegfilgrastim. All patients engrafted neutrophils and platelets with a median of 10 and 18 days, respectively. The incidence of febrile neutropenia was 49% (18/37). Neutrophil engraftment results were compared to a historical cohort of patients who received no growth factors or prophylactic filgrastim after ASCT. Time to neutrophil engraftment using pegfilgrastim was comparable to daily filgrastim and was shorter than in a historical group receiving no filgrastim (10 vs 13.7 days, P<0.001). Pegfilgrastim given as a single fixed dose of 6 mg appears to be safe after HDC and ASCT. It accelerates neutrophil engraftment comparable to daily filgrastim after ASCT. Pegfilgrastim may be convenient to use in outpatient transplant units.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Bearman SI, Appelbaum FR, Back A et al. Regimen-related toxicity and early posttransplant survival in patients undergoing marrow transplantation for lymphoma. J Clin Oncol 1989; 7: 1288–1294.

    Article  CAS  Google Scholar 

  2. Schmitz N, Dreger P, Zander AR et al. Results of a randomised, controlled, multicentre study of recombinant human granulocyte colony-stimulating factor (filgrastim) in patients with Hodgkin's disease and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation. Bone Marrow Transplant 1995; 15: 261–266.

    CAS  Google Scholar 

  3. Bence-Bruckler I, Bredeson C, Atkins H et al. A randomized trial of granulocyte colony-stimulating factor (Neupogen) starting day 1 vs day 7 post-autologous stem cell transplantation. Bone Marrow Transplant 1998; 22: 965–969.

    Article  CAS  Google Scholar 

  4. Molineux G, Kinstler O, Briddell B et al. A new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans. Exp Hematol 1999; 27: 1724–1734.

    Article  CAS  Google Scholar 

  5. Molineux G . Pegylation: engineering improved biopharmaceuticals for oncology. Pharmacotherapy 2003; 23: 3S–8S.

    Article  CAS  Google Scholar 

  6. Molineux G . The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta). Curr Pharm Des 2004; 10: 1235–1244.

    Article  CAS  Google Scholar 

  7. IBMTR Core Instruction Manual 2/2002, version 2, pp 22–23.

  8. Holmes FA, Jones SE, O’Shaughnessy J et al. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Ann Oncol 2002; 13: 903–909.

    Article  CAS  Google Scholar 

  9. Holmes FA, O’Shaughnessy JA, Vukelja S et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle vs daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 2002; 20: 727–731.

    Article  CAS  Google Scholar 

  10. Green MD, Koelbl H, Baselga J et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim vs daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003; 14: 29–35.

    Article  CAS  Google Scholar 

  11. Bensinger W, Appelbaum F, Rowley S et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 1995; 13: 2547–2555.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This research was supported by Amgen Inc. (Thousand Oaks, CA, USA). We thank Vanderbilt Ingram Cancer Center Clinical Trials Office for conduct of the study and data collection.

Author information

Authors and Affiliations

  1. Division of Hematology-Oncology, Vanderbilt Ingram Cancer Center, Nashville, TN, USA

    M H Jagasia, J P Greer, D S Morgan, S Mineishi, A A Kassim, K L Ruffner & F G Schuening

  2. Department of Preventive Medicine, Department of Medicine, Vanderbilt Ingram Cancer Center, Nashville, TN, USA

    H Chen

Authors
  1. M H Jagasia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J P Greer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D S Morgan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S Mineishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A A Kassim
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. K L Ruffner
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. H Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. F G Schuening
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M H Jagasia.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jagasia, M., Greer, J., Morgan, D. et al. Pegfilgrastim after high-dose chemotherapy and autologous peripheral blood stem cell transplant: phase II study. Bone Marrow Transplant 35, 1165–1169 (2005). https://doi.org/10.1038/sj.bmt.1704994

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704994

Keywords

This article is cited by

Search

Advanced search

Quick links